Older Adults Remain Underrepresented in Clinical Trials Despite Higher Disease Risk
Experts advise prospective participants to focus on the scientific question being answered and to verify compensation details before enrolling.
By Charles Reed ·

Studies indicate that older adults are frequently excluded from clinical trials, even though many medical conditions affect this demographic at higher rates. This exclusion creates a gap in medical knowledge regarding how new treatments function in aging bodies.
Dr. Rhea Rogers, a board-certified physician, advises that prospective participants should shift their focus away from personal outcomes and toward the study's objective. "I think the first thing we have to do is not think about, ‘Can this clinical trial help me?’ but ‘What is this clinical trial trying to answer?’" Rogers said. "That’s what most of these trials are about."
Rogers notes that many individuals view clinical trials as a final option after other treatments have failed. She argues that enrollment offers immediate access to emerging therapies, devices, and medicines that may not be available to the general public for years.
Potential participants can locate studies through ClinicalTrials.gov, by consulting their primary care physician, or by contacting academic centers and disease-specific organizations. Amy O’Rourke, an aging expert, pointed out that the National Institutes of Health maintains a list of clinical trials and identifies which ones provide financial compensation.
Participants must understand that they may receive a placebo rather than the experimental drug. "You might be the one getting the placebo, you might get the drug itself," O’Rourke said. "So knowing that going in, the expectation wouldn’t be that I’m going to get the drug or that I’m going to see if I’m going to get better."
O’Rourke also highlighted the non-medical benefits of participation. She reported that clients who joined a local trial group found value in the social support and community resources provided by on-site social workers.
Gerontologist “Sam” Cradduck explained that medication metabolism differs between older and younger adults. Without data from older participants, doctors often lack clear guidance on dosing and safety. "Medication metabolizes so differently in our older community than it does in our younger community, so without having them as participants, they’re often walking blind," Cradduck said.
Cradduck addressed the common fear of being a "guinea pig." She stated that by the time a treatment reaches the clinical trial phase, it has undergone repeated testing. "You’re not a guinea pig," she said. "By the time it’s reached this point, it has been thoroughly tested repeatedly."






